Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The role of adjuvant chemotherapy (ACT) for patients with stage IB–IIA non‐small cell lung cancer (NSCLC) according to the eighth edition of the AJCC TNM staging system remains controversial.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Data were collected from patients with NSCLC stage IB–IIA according to the eighth edition of the AJCC TNM staging system who underwent surgical resection from 2008 to 2015. The relationship between ACT and overall survival (OS) or disease‐free survival (DFS) was analyzed using the Kaplan–Meier method and Cox proportional hazards model.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The study included 648 patients with completely resected NSCLC stage IB–IIA; 312 underwent ACT after surgical resection and 336 were placed under observation. After propensity score matching, 247 pairs of patients were matched and the five‐year OS was 88.08% and 83.12% (<i>P</i> = 0.13) in ACT and non‐ACT settings, respectively. Subgroup analyses demonstrated that ACT treatment was correlated with an improved five‐year OS in patients with visceral pleural invasion (VPI) in the 3 < tumor ≤ 4 cm subgroup (93.98% and 68.93%, <i>P</i> < 0.01). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>ACT was not significantly associated with improved five‐year OS in stage IB–IIA NSCLC patients. However, further subgroup analysis showed that patients with VPI in the 3 < tumor ≤ 4 cm (T2aN0M0, stage IB) subgroup might benefit more from ACT. Further studies are required to validate the findings and better systemic strategies need to be developed in these patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><ul class="unordered-list"><li>For patients with stage IB–IIA NSCLC according to the eighth edition of the AJCC TNM staging system, the effect of ACT remains unclear.</li><li>ACT was not significantly associated with improved five‐year OS in stage IB–IIA NSCLC patients. However, it was correlated with better DFS before or after PSM.</li><li>Patients with VPI in the 3 < tumor ≤ 4 cm subgroup may benefit from ACT.</li></ul></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><ul class="unordered-list"><li>ACT was not significantly associated with improved five‐year OS in stage IB–IIA NSCLC patients. However, it was correlated with better DFS before or after PSM.</li><li>Patients with VPI in the 3 < tumor ≤ 4 cm subgroup may benefit from ACT.</li></ul></section>

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences

Propensity-matched Analysis of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small-cell Lung Cancer Patients

Survival Analysis of Non-Small Cell Lung Cancer Patients with Adjuvant Chemotherapy.

High-risk Characteristics of Pathological Stage I Lung Adenocarcinoma after Resection: Patients for Whom Adjuvant Chemotherapy Should Be Performed

Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC

Adjuvant chemotherapy improves survival in surgically resected stage IB squamous lung cancer.

Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection

Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components

Survival Benefit of Adjuvant Chemotherapy for Patients with Poorly Differentiated Stage IIA Colon Cancer

Prognostic Significance and Survival Benefits of Postoperative Adjuvant Chemotherapy in Patients with Stage IA Lung Adenocarcinoma with Non-Predominant Micropapillary Components

Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy

Adjuvant Chemotherapy for Isolated Resectable Colorectal Lung Metastasis: A Retrospective Study Using Inverse Probability Treatment Weighting Propensity Analysis

Adjuvant Chemotherapy on Survival of Patients with Stage IB Non‑small Cell Lung Cancer: a Comparison Study with Propensity Score Matching

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer

Micropapillary or Solid Pattern Predicts Recurrence Free Survival Benefit from Adjuvant Chemotherapy in Patients with Stage IB Lung Adenocarcinoma.

Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection

High-risk features associated with recurrence in stage I lung adenocarcinoma

Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection

Clinical, Imaging, and Pathological-Molecular Characteristics Associated with Stage IA Invasive Lung Adenocarcinoma Recurrence After Sub-lobar Resection

Late recurrence of completely resected stage I to IIIA lung adenocarcinoma

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma